Theravance Inc  

(Public, NASDAQ:THRX)   Watch this stock  
Find more results for THRX
22.00
-0.94 (-4.10%)
Jul 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 21.82 - 22.67
52 week 20.25 - 34.55
Open 22.53
Vol / Avg. 0.00/1.55M
Mkt cap 2.48B
P/E     -
Div/yield 0.25
EPS -1.84
Shares 112.52M
Beta 1.59
Inst. own 79%
Jul 24, 2014
Q2 2014 THERAVANCE INC Earnings Release (Estimated)
Jun 4, 2014
THERAVANCE INC at Jefferies Global Healthcare Conference
May 22, 2014
THERAVANCE INC 2014 Annual Shareholder Meeting
May 13, 2014
THERAVANCE INC at Bank of America Merrill Lynch Health Care Conference
May 6, 2014
Q1 2014 THERAVANCE INC Earnings Conference Call
May 6, 2014
Q1 2014 THERAVANCE INC Earnings Release
Apr 30, 2014
Theravance Inc. Conference Call to discuss the results from a Phase 2 Study of TD-9855 in Patients With Fibromyalgia
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -41032.12% -3587.66%
Operating margin -40147.88% -3549.03%
EBITD margin - -3376.63%
Return on average assets -42.22% -32.52%
Return on average equity -96.57% -75.17%
Employees 241 -
CDP Score - -

Address

901 GATEWAY BLVD
SOUTH SAN FRANCISCO, CA 94080
United States - Map
+1-650-8086000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Theravance, Inc. (Theravance) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. The Company is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. Its programs include RELVAR or BREO (fluticasone furoate/vilanterol), ANORO (umeclidinium bromide/vilanterol) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc (GSK), and its oral Peripheral Mu Opioid Receptor Antagonist program. In June 2014, the Company announced the completion of separation of Theravance Biopharma Inc, research and development-based biopharmaceutical business.

Officers and directors

Rick E. Winningham Chairman of the Board, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Michael W. Aguiar Chief Financial Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Bradford J. Shafer Esq. Senior Vice President, General Counsel, Secretary
Age: 54
Bio & Compensation  - Reuters
George B. Abercrombie Senior Vice President - Corporate Partnerships, Commercial
Age: 59
Bio & Compensation  - Reuters
Leonard M. Blum Chief Commercial Officer, Senior Vice President
Age: 53
Bio & Compensation  - Reuters
Jeffrey D. Jonker Senior Vice President - Corporate and Business Development
Age: 41
Bio & Compensation  - Reuters
Junning Lee Senior Vice President - Technical Operations
Age: 57
Bio & Compensation  - Reuters
Mathai Mammen M.D., Ph.D. Senior Vice President - Research & Early Clinical Development
Age: 46
Bio & Compensation  - Reuters
Frank Pasqualone Senior Vice President - Operations
Age: 58
Bio & Compensation  - Reuters
Theodore J. Witek Jr. Senior Vice President - Corporate Partnerships, Clinical and Medical Affairs
Bio & Compensation  - Reuters